An open‐label, phase II study of patritumab deruxtecan (HER3‐DXd, U3‐1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.